Login to Your Account



Money, Policy Changes Still Needed

Geron's Gamble Pays Off; ESCs Making Headway

By Jennifer Boggs


Monday, February 2, 2009
By gaining the FDA's blessing for the first clinical trial of an embryonic stem cell (ESC)-based therapy, Geron Corp. injected a newfound enthusiasm for the space, helped, in part, by the anticipated loosening of federal funding restrictions by the newly sworn in Obama administration.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription